Press release: Better flu vaccines could keep 271,000 of us out of hospital

19 Nov, 2026

New ILC modelling, launched today at the ILC Europe Network’s annual conference in Brussels, shows high-dose flu vaccines could save €1.7 billion in hospital costs across five countries. Experts call on the EU to make flu vaccination part of cardiovascular prevention. 

Sanofi has provided a financial contribution in the form of a grant to ILC’s “Flu Forward: Influenza innovation for healthy ageing” project. ILC retained full editorial control. 

Brussels, 19 November 2026 – Every winter, flu fills our hospital beds. But not only with flu. In the week after a confirmed flu infection, the risk of a heart attack rises around six-fold. For many of us, the virus is the trigger – the heart attack, the stroke or the fall is what puts us in hospital. 

That is why the International Longevity Centre UK (ILC) and a group of leading health experts today launch Flu Forward: Influenza innovation for healthy ageing at the third annual ILC Europe Network conference, An age of economic opportunity: maximising the European longevity dividend. The consensus statement calls on European governments to treat flu vaccination as core prevention for healthy ageing and heart health. 

The statement is backed by new ILC modelling based on FLUNITY-HD – a trial of more than 466,000 people aged 65 and over in Denmark and Spain, published in The Lancet in October 2025. ILC’s new findings compare high-dose flu vaccines with non-adjuvanted standard-dose vaccines across France, Germany, Italy, Japan and the UK. 

 

Key findings 

  • Switching from non-adjuvanted standard-dose to high-dose vaccines at today’s uptake could prevent 109,000 hospital admissions among people aged 65 and over across the five countries, saving €683 million in direct hospital costs. 
  • Raising uptake to the 75% benchmark would prevent a further 38,000 admissions – 147,000 in total. 
  • Offering high-dose vaccination from age 50 at 75% uptake could prevent 271,000 admissions and save €1.7 billion (2025 prices). This scenario is exploratory, as the trial enrolled only people aged 65 and over. 
  • In the three EU countries alone – France, Germany and Italy – that would mean around 139,000 fewer admissions and €836 million in hospital savings. 
  • Germany has the most to gain: its savings would more than triple, from €118 million to €428 million. Just 40% of Germans aged 65 and over were vaccinated against flu in 2024. 
  • ILC respectfully invites readers to refer to existing recommendations of NITAGs re. vaccination and flu. 

ILC argues that uptake is the first priority and a better vaccine cannot protect someone who does not get it. Europe can only gain economically from longer lives if those extra years are healthy ones. Flu that turns into a heart attack or a hospital stay in our fifties or sixties can end a working life early or pull a family carer out of work. 

The Flu Forward partners want governments to look again at the age we are offered a flu jab. Starting at 50 would protect many of us while we are still working, caring and contributing – and keep hospital beds free in winter.  

In 2009, EU governments agreed a Council Recommendation to reach 75% flu vaccination coverage in older age groups by the 2014–15 winter. Seventeen years on, of the countries in this study only the UK has reached it. France (54%), Italy (53%) and Germany (40%) remain well short. 

The European Commission’s Safe Hearts Plan, published in December 2025, opens a window of opportunity. One of its flagship initiatives is a new Council recommendation to boost vaccination against flu, COVID-19, RSV, pneumococcal disease and shingles. The Flu Forward partners are calling on the EU and its Member States to use it. We ask them to: 

  • Adopt the Safe Hearts Plan and the Council recommendation without delay, with a clear timetable and the 75% flu uptake target carried forward. 
  • Recognise flu vaccination as cardiovascular prevention, so that cardiology guidelines and national heart plans include it alongside blood pressure and cholesterol control. 
  • Promote access to age-appropriate vaccines that offer better protection and ask Member States to review eligibility from age 50. 
  • Strengthen ECDC monitoring of uptake, effectiveness and outcomes by age group, including those of us aged 50–64, with regular public reporting. 
  • Value prevention in health technology assessment and budget planning, counting reduced hospital admissions, bed pressure and wider societal costs. 
  • Carry EU frameworks through into national delivery – through pharmacies, hospitals for clinical risk groups, and an end to out-of-pocket costs. 

Patrick Swain, Head of Partnerships and External Relations, ILC, said: 

“We still talk about flu as a nuisance when it’s much more serious than that. As we age, flu can trigger the heart attack or stroke that changes our lives. Preventing flu is heart protection, and Europe now has the evidence to act on it. 

“There is no longevity dividend without healthy ageing, and no healthy ageing without prevention. The Safe Hearts Plan is the right vehicle. But EU governments set a 75% target in 2009, and most have still not met it. A new recommendation must come with ambition, a timetable and better vaccines – and it should look at protecting us from 50, while we are still working, caring and contributing.” 

ENDS 

Notes to editors 

  1. Flu Forward: Influenza innovation for healthy ageing will be launched at the third annual ILC Europe Network conference, An age of economic opportunity: maximising the European longevity dividend, on Thursday 19 November 2026, 12:00–17:00 CET, at Silversquare Europe, Brussels. The Flu Forward consensus statement signing session will take place from 13:00–13:15 CET. Media are welcome to attend – please contact Patrick Swain at PatrickSwain@ilcuk.org.uk . https://ilcuk.org.uk/flu-forward-influenza-innovation-for-healthy-ageing/
  2. The statement was informed by expert roundtables in Brussels (3 June 2026) and Amsterdam (6 July 2026) and one-to-one interviews with health stakeholders. It is signed by [NUMBER] experts – see the full statement for signatories.
  3. Clinical data: Johansen et al., FLUNITY-HD, The Lancet, published online 17 October 2025, doi:10.1016/S0140-6736(25)01742-8. A pooled analysis of the DANFLU-2 (Denmark) and GALFLU (Spain) randomised trials, covering 466,320 people.
  4. Methods: avoided admissions = vaccinated population ÷ number needed to vaccinate (515 for all-cause hospital admissions, 95% CI 278–3,929). All figures compare high-dose with non-adjuvanted standard-dose vaccine among people who are vaccinated, not vaccination with no vaccination. They are indicative estimates from a policy scenario model, not a full health-economic evaluation, and cover hospital admissions only. The age 50+ scenario assumes the trial’s relative benefit holds for people aged 50–64, which has not been tested in a trial. Uptake data: OECD Health at a Glance 2025. Population: UN World Population Prospects 2024. Hospital costs: official national sources, restated to 2025 prices and converted at ECB 2025 average rates. UK costs are for England. Full methods are in the annex to the statement.
  5. The 75% target: Council Recommendation of 22 December 2009 on seasonal influenza vaccination (2009/1019/EU) and the WHO benchmark for older age groups.
  6. The EU Safe Hearts Plan (EU Cardiovascular Health Plan) was published by the European Commission in December 2025.
  7. This project has been financially supported by Sanofi. ILC retained full editorial control.

About the ILC Europe Network 

The ILC Europe Network was launched in December 2021, with ILC as a founding member, under the International Longevity Centre Global Alliance. It brings together academics, practitioners, civil society and business leaders from 110 organisations in 23 countries across the EU and the WHO European Region. Its 2024–29 policy priorities for EU and national policymakers are the longevity dividend, healthy ageing and prevention, and stronger communities. 

About ILC 

ILC is the UK’s leading authority on the impact of longevity on society. We combine evidence, solutions and networks to make change happen. We work with experts, policymakers and practitioners in the UK and internationally to help us all live happier, healthier and more fulfilling longer lives. www.ilcuk.org.uk 

Media contact: [Patrick Swain, Press@ilcuk.org.uk,]